Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy

Onal, Cem; Güler, Ozan Cem; Reyhan, Mehmet; Yapar, Alı Fuat

doi:10.1016/j.ygyno.2015.01.542

Cited by 41 publications

(29 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 Previous studies by Grigsby et al 8 ]-FDG PET in pelvic lymph nodes and found that patients with a higher SUV max in the pelvic lymph nodes have a statistically significant worse disease-specific survival and OS. These results were recently corroborated by Onal et al, 12 who found that patients with highly FDG-avid pelvic lymph nodes had worse disease-specific survival and OS.…”

supporting

confidence: 59%

Prognostic Significance of the Standardized Uptake Value of Pretherapeutic 18F-Labeled 2-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in Patients With Locally Advanced Cervical Cancer

Gubbi

Kacheria

Ahmad³

et al. 2017

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

supporting

confidence: 59%

Prognostic Significance of the Standardized Uptake Value of Pretherapeutic 18F-Labeled 2-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in Patients With Locally Advanced Cervical Cancer

Gubbi

Kacheria

Ahmad³

et al. 2017

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…Progressive disease was signaled by excessive 18-fluorodeoxyglucose uptake (relative to background hepatic level) at sites of initial or suspected residual disease, with at least 20% increase in maximum dimension on imaging, histologic support, or evidence of lymphadenopathy. 20 Patients were classified as showing a non-CR if a residual tumor or locoregional or distant metastasis was detected or if death occurred during follow-up.…”

Section: Clinical Follow-upmentioning

confidence: 99%

The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy

Onal¹,

Yıldırım²,

Güler³

et al. 2018

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to investigate the prognostic significance of pretreatment and posttreatment lymphopenia in locally advanced squamous cell carcinoma (SCC) cervical cancer patients treated with definitive chemoradiotherapy (ChRT).MethodsData from 95 patients with SCC were retrospectively analyzed. Relationships between pretreatment or posttreatment lymphopenia and patient or tumor characteristics, and overall survival (OS) and disease-free survival (DFS) were evaluated.ResultsMedian follow-ups for the entire cohort and survivors were 68 months (range, 3–133 months) and 88 months (range, 22–133 months), respectively. Ten patients (11%) exhibited pretreatment lymphopenia, whereas 58 patients (61%) exhibited posttreatment lymphopenia. Median pretreatment total lymphocyte counts decreased from 2029 cells/μL to 506 cells/μL 2 months after ChRT (P < 0.001). The 5-year OS and DFS rates were significantly higher in patients without pretreatment lymphopenia compared with patients with pre-retreatment lymphopenia (61% vs 20% [P < 0.001], 55% vs 20% [P < 0.001]). Patients without posttreatment lymphopenia had significantly higher 5-year OS and DFS rates than their counterparts (70% vs 46% [P = 0.02], 70% vs 39% [P = 0.004]). Complete response (CR) was observed in significantly fewer patients with pretreatment lymphopenia than in those without, after ChRT. Patients with posttreatment lymphopenia had higher rates of lymph node metastasis (P = 0.001) and lower posttreatment CR rates (P = 0.01) versus patients without posttreatment lymphopenia. In univariate analysis, International Federation of Gynecology and Obstetrics stage, tumor size, lymph node metastasis, and treatment response were prognostic for OS and DFS. In multivariate analysis, pretreatment lymphopenia, lymph node metastasis, and treatment response were independent predictors of OS and DFS. Age was predictive of OS. Tumor size was prognostic for DFS.ConclusionsPretreatment lymphopenia and posttreatment lymphopenia are associated with worse treatment response in patients given ChRT for cervical SCC. Pretreatment lymphopenia is predictive for OS and DFS. Therapeutic strategies including pretreatment or posttreatment immune preservation or modulation may improve response rates and survival in women with cervical SCC.

show abstract

“…6 In locally advanced cervical cancer (LACC), highly FDG-avid pelvic lymph nodes have a higher risk of disease recurrence with worse survival. 7 However, studies of the clinical significance of intratumor FDG uptake are limited, and yet no definitive data are present.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer

Cima

Perrone

Castellucci

et al. 2018

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy

Cited by 41 publications

References 18 publications

Prognostic Significance of the Standardized Uptake Value of Pretherapeutic 18F-Labeled 2-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in Patients With Locally Advanced Cervical Cancer

Prognostic Significance of the Standardized Uptake Value of Pretherapeutic 18F-Labeled 2-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in Patients With Locally Advanced Cervical Cancer

The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy

Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer

Contact Info

Product

Resources

About